MorphoSys AG
XETRA:MOR
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
17.8
69.35
|
| Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
MorphoSys AG
MorphoSys AG
Cash from Operating Activities
MorphoSys AG
Cash from Operating Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
MorphoSys AG
XETRA:MOR
|
Cash from Operating Activities
-€298.2m
|
CAGR 3-Years
-11%
|
CAGR 5-Years
-58%
|
CAGR 10-Years
N/A
|
|
|
BioNTech SE
NASDAQ:BNTX
|
Cash from Operating Activities
€5.4B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
CureVac NV
NASDAQ:CVAC
|
Cash from Operating Activities
-€267.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-29%
|
CAGR 10-Years
N/A
|
|
|
Immatics NV
NASDAQ:IMTX
|
Cash from Operating Activities
€18.2m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-3%
|
CAGR 10-Years
N/A
|
|
|
Biotest AG
XETRA:BIO
|
Cash from Operating Activities
-€2.7m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
33%
|
CAGR 10-Years
30%
|
|
|
Formycon AG
XETRA:FYB
|
Cash from Operating Activities
-€9.8m
|
CAGR 3-Years
-33%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
MorphoSys AG
Glance View
MorphoSys AG engages in the development of antibodies for therapeutic, diagnostics, and research applications. The company is headquartered in Planegg, Bayern and currently employs 648 full-time employees. The firm develops drugs using its own research and development, as well as in cooperation with pharmaceutical and biotechnology partners. The firm's operating segments include Proprietary Development and Partnered Discovery. In the Proprietary Development segment, it develops therapeutic antibodies and peptides in the area of inflammatory disease and oncology. In the Partnered Discovery segment, the Company applies technologies for the research, development and optimization of therapeutic antibodies as drug candidates. The firm develops new treatments for patients suffering from serious diseases. Its technologies include HuCAL, which is a collection fully human antibodies and a system for their optimization; Ylanthia, which is an antibody library in Fab format, and Slonomics, an automated technology for gene synthesis and modification for the generation of gene libraries in a controlled process.
See Also
What is MorphoSys AG's Cash from Operating Activities?
Cash from Operating Activities
-298.2m
EUR
Based on the financial report for Mar 31, 2024, MorphoSys AG's Cash from Operating Activities amounts to -298.2m EUR.
What is MorphoSys AG's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 5Y
-58%
Over the last year, the Cash from Operating Activities growth was -1%. The average annual Cash from Operating Activities growth rates for MorphoSys AG have been -11% over the past three years , -58% over the past five years .
You don't have any saved screeners yet
